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Translations

for friends and colleagues of the Department of Medicine

Department of Medicine Champions
Length-of-Stay Initiative
Inpatient care at Jefferson, like at all academic
medical centers — which treat patients while
they train doctors — is complex, with dozens
of key players, both at the patient’s bedside
and behind the scenes. In September 2008,
the Department of Medicine began a rigorous
process for improving the management of
patients’ length of stay (LOS). The goals are to

“Huddles” are being used to streamline inpatient
care and reduce patients’ length of hospital stay.
Attendings, house staff, nurse managers, therapists,
and case managers convene each morning to improve
communications and efficiency.

maintain first-rate quality of care, identify
barriers hindering an efficient process, and
create systems to support a streamlined approach.
“Decreasing LOS for our patients serves two
important ends,” explains Karen Javie, RN, MSN,
Vice President for Strategic Initiatives at the
University. “First, shorter hospital stays are in
our patients’ best interest. Research has shown
the longer the stay, the greater the incidence
of developing additional health risks and
complications. Second, it reduces medical costs
to the patient, insurer, physician, and hospital —
all of which are critical in the current climate
of escalating health care costs,” Ms. Javie says.
“The Jefferson leadership recognized that it
was time to make the necessary cultural shift.”
As leader of the initiative, Arthur Feldman,
MD, PhD, the Magee Professor and Chair of
Medicine, drew on expertise from the Chartis
Group, a health care consulting firm and
formed a multidisciplinary oversight committee
to develop a plan to tackle this formidable task.
He also convened five subcommittees:
Physician Leadership, Information Technology,
Evidence-Based Medicine, Resources, and
Non-Teaching Hospitalists. These teams
completed the initial work by December 2008,
and Dr. Feldman delivered a Grand Rounds in
January 2009, when he shared the outcomes
and subcommittee recommendations.
Continued on page 7
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From the

Chairman
As we near the decade’s
end, the Department of
Medicine continues to
break new ground and
celebrate numerous
successes. Some of
our achievements are
behind-the-scenes, like the work of our intrepid
researchers at the Center for Translational
Medicine. Other milestones are making headlines,
such as the 25th anniversary of the region’s first
liver transplant.
Our lead story announces our recent Length-of-Stay
Initiative, which is promoting the most effective,
efficient care for our patients while improving
administrative and communication processes and
reducing costs. We also feature the research of Dr.
Rabinowitz, in gene therapy, and Dr. Peppel, in
vascular remodeling. For our clinical activities, we
spotlight Endocrinology’s new protocols for our
diabetic inpatients and Dr. Kane’s leadership for
Residents as well as Pulmonary/Critical Care. We
are enthusiastic about the new career pathways
designed to train residents in new, customized ways.
Much of this work is possible thanks to our
generous donors, such as Mr. Scarperi (featured
on page 5). With their help we look forward to
the next 10 years of providing excellent patient
care, first-rate medical education, and significant
research outcomes. Please also visit our website
at www.jefferson.edu/medicine for more in-depth
articles and updates.

Arthur M. Feldman, MD, PhD
Magee Professor of Medicine and
Chairman of the Department
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Learning from How Blood Vessels Heal
Molecular biologist Karsten Peppel, PhD,
Associate Professor, joined the Center for
Translational Medicine in 2006. He came
to the U.S. from Germany in 1984, to study
at SUNY Albany and then trained at Duke
University. His lab studies the role of
inflammation in vascular remodeling.

common in type-2 diabetes — the collaterals
do not open up adequately, there are not
enough new blood vessels, and problems
like necrosis and gangrene can set in. We
investigate these and other instances of
dysfunctional vascular remodeling.

Can you explain vascular remodeling?

Acute inflammation protects organisms from
injury and infection, but chronic inflammation drives vascular dysfunction and seems to
be a common thread that runs
through many chronic diseases,
including Alzheimer’s, type-2
diabetes, atherosclerosis, and
cardiac disease. Chronic vascular inflammation can lead
to the formation of clots that
can cause heart attacks.

The term describes how the blood vessel
structure changes after injury. If you tear a

What is the role of inflammation?

What mediates the
inflammation?
We are studying Tumor
Necrosis Factor (TNF),
which has two receptors
(TNFR1 and TNFR2). We
are investigating how these
receptors contribute to
Karsten Peppel, PhD, examines a blood vessel through a macro-view fluorescence vascular remodeling following
injury. We already knew that
microscope in researching the role of inflammation in vascular remodeling.
signals from the TNFR1 could
be toxic to endothelial cells (which line the
muscle, or a blood clot forms in an artery,
blood vessels, keep blood flowing, and prevent
blood flow is cut off. Small vessels that
clotting). We were surprised that TNFR1 also
connect major arteries (called collaterals)
supports the growth of smooth muscle cells,
open up and undergo structural changes to
which underlie the endothelium and can
expand and strengthen and form new vessels
strengthen the vessels after injury. TNFR2
that provide more blood to the injured tissue.
can even aid endothelial cells after injury.
In diseases such as peripheral arterial disease —

You also conduct research on vein grafts.
In a coronary artery venous bypass graft,
which uses a leg vein to bypass the blocked
artery, these veins have 40–50% failure rate
after two years. There are few options for
patients with blocked vein grafts. Nature
simply has not designed veins to handle the
same kind of stress that arteries can handle.
So the vein develops more smooth muscle cells,
to have a firmer structure. If this process stops
at the right time, the vein remains open and
can handle arterial blood flow. But if the vein
wall becomes too thick, it eventually blocks
the blood flow. This is where our discovery
of the opposing effects of TNF receptors in
vascular remodeling became so significant.

How will your research help patients?
One goal is to help clinicians assess a patient’s
risk for vascular disease. Typically when we
look for common risk factors, we look for LDL
(low-density lipoprotein) levels and total lipid
levels. Examining the patient’s inflammatory
markers gives us more information. High
levels of inflammatory markers suggest a
greater risk for vascular disease.
We are looking at factors that may keep
patients from forming new vessels efficiently
and how we can boost the required
mechanisms to do this. A logical next step
is to explore the possibility to selectively
activate the TNFR2, and at the same time
prevent signaling emanating from the TNFR1.
This would shift the balance of chronic
inflammatory signaling and could promote
a faster recovery after injury. ■

Targeting Viruses That Work Against Heart Failure
Cardiovascular disease accounts for nearly 40
percent of all deaths that occur in the U.S. each
year, and the cost to our economy is a staggering
$394 billion. Joseph E. Rabinowitz, PhD,
Assistant Professor at the Center, devotes
his research to the study and creation of
vectors (such as viruses) that are essential to
the delivery of a progressive treatment called
gene therapy.
Dr. Rabinowitz and Center Director Walter
Koch, PhD, have the ambitious task of
removing disease-causing genes and inserting
therapeutic ones in their place. Dr. Koch has
focused on how to use gene transfer to treat

cardiovascular disease, and he has successfully
used the technique to halt heart failure in
mice. The Center focuses on replicating this
research in other animals, so that it may
ultimately be approved for clinical research
in humans. “One of the keys to breaking the
clinical barrier with gene transfer,” explains
Dr. Rabinowitz, “is finding a safe and effective
mechanism for gene delivery to the heart.”
His work is to create that vector.

Why use viruses?
Viruses — once they have been genetically
altered to deliver normal DNA — are
vectors currently used in gene therapy.

https://jdc.jefferson.edu/translations/vol4/iss2/1
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Dr. Rabinowitz and his lab are researching
the use of the adeno-associated virus (AAV),
which causes very little immune response
in humans. AAV is first modified with the
desired therapeutic gene, and then it infects
the targeted cells with the genetic material that
will help the cell counteract the disease.

Which viruses to use?
Using basic research, Dr. Rabinowitz
identifies and creates specific viruses for these
incredibly precise purposes. His team injected
mice in their tail veins with a version of AAV
containing the gene for firefly luciferase
(which causes fireflies to glow). They then
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Endocrinology

New Protocols for Hospital Patients with Diabetes
Mean Better Outcomes
Glycemic control is a delicate balancing act for
people managing their diabetes at home, and the
same is true for physicians treating diabetic patients
in the Intensive Care Unit (ICU). Particularly
with insulin-dependent diabetes, the goal of
keeping blood sugar levels in a healthy range
is a complicated matter. Too little insulin can
result in hyperglycemia or high blood sugar levels;
too much insulin can result in hypoglycemia, or
low blood sugar levels. Hypoglycemic incidents
can be fatal, especially in critically ill patients.
This year, the American Association of Clinical
Endocrinologists (AACE) and the American
Diabetes Association (ADA) have revised the
glucose targets for ICU patients, in an effort to
reduce hypoglycemic incidents and morbidity.
Jefferson’s Division of Endocrinology is well
positioned to implement the changes thanks to
the Jefferson Insulin Infusion Protocol (JIIP),
first developed in 2005.
The JIIP protocol has recently translated into
dramatically improved patient outcomes.
Jefferson has among the lowest incidence of
hypoglycemia — less than 1 percent, whereas
most health care centers are in the range of
5 to 20 percent.
Jefferson’s endocrinology team is led by Serge
Jabbour, MD, Associate Professor of Medicine,
and Kevin Furlong, DO, Clinical Assistant
Professor. In 2005, they realized the need for a
standardized approach to glycemic control of

ICU patients and began to develop the JIIP in
collaboration with the Departments of Pharmacy
and Nursing; JeffIT; the ICU team; and Paul
Marik, MD, former Director of the Division of
Pulmonary and Critical Care.
Advances in technology have improved the team’s
ability to manage glycemic levels. Dr. Jabbour
explains, “JeffIT created an electronic system that
allows us to enter a patient’s sugars and obtain
what change in insulin drip rate is needed.”
Since the 2009 recommendations and the new
technology, the team has shown great results —
less than 1 percent incidence of hypoglycemia.
“Before JIIP,” says Dr. Jabbour, “patients would
be started on an insulin drip, and the nurse or
resident would have to do titration and make
a decision about what was appropriate. Now
we have one unified protocol for every floor
of the hospital.”
What was previously considered a correctional
dose of insulin is also now scaled to the
individual patient’s needs based on his or her
body mass index (BMI). “JIIP has also become
more customized,” explains Dr. Furlong,
“because a patient with type-1 diabetes who
weighs 90 pounds responds more dramatically
to 2 units of insulin drips than a patient with
type-2 diabetes who weighs 250 pounds.”
While the JIIP has helped tremendously with
diabetes care in the ICU, glycemic control still

Endocrinology’s Serge Jabbour, MD (left), and Kevin
Furlong, DO (middle), study data from the electronic
patient records system, which has been customized to
standardize care of inpatients with diabetes.

is not easy. “What would be ideal,” says Dr.
Jabbour, “would be a continuous glycemic
monitor, much like the oxygen monitors that
we use now, which merely clip onto a finger
like a clothespin.” He explains that the current
finger-stick method to monitor blood sugars
is too invasive and infrequent to do real-time
monitoring. He hopes that real-time monitoring
will be the next step for the JIIP. Jeffrey Joseph,
MD, Director of the Jefferson Artificial Pancreas
Center, is developing real-time glucose sensors.
To date, clinical trials have been encouraging. ■

Targeting Viruses
Continued from previous page

took special “bioluminescence” images of
the animals 1, 2, 4, 8 and 12 weeks after the
injection and measured the photons each
animal emitted. The imaging revealed various
levels of expression for the various vectors.
They next dissected the animal tissue to
identify which vectors went most readily to
which organs. Given that AAV9 and AAV6
were readily observed in the heart, these two

Joseph Rabinowitz, PhD, inserts an ultra high speed
centrifuge rotor into an ultra centrifuge, where viruses
are harvested for use in gene therapy.
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vectors were identified as most effective for
gene therapy related to cardiovascular disease.
“Ideally, this would lead to doctors injecting
cells in a diseased area — such as the heart or
lungs — with the vector that is most effective
for that organ,” says Dr. Rabinowitz. “This
therapeutic gene, once unloaded, supports
the cell in producing a functional protein
that counteracts the disease.” The hope is
that one day, this research will translate into
gene therapy to combat the high rate of heart
disease worldwide. ■

3

Jefferson Translations, Vol. 4 [2010], Iss. 2, Art. 1

Hepatology

State-of-the-Art Liver Transplant Care Celebrates 25 Years
In May the Liver Transplantation Program at
Jefferson celebrated the 25th anniversary of
the Delaware Valley’s first liver transplant.
Michael Donahue, Jefferson’s first liver
transplant patient, was in attendance at the event.
“It’s a blessing. I’ve been able to get married,
have children, have a career — live a normal
life,” said Mr. Donahue in a KYW interview.
“It’s truly been a gift of life.” Since that
operation in 1984, Jefferson physicians have
performed more than 500 transplants.
Victor J. Navarro, MD, Medical Director of
the Hepatology and Liver Transplantation
Program, notes that a successful transplantation
is the result of coordinated efforts from an entire
team. “Our four transplant surgeons play a critical
role,” says Dr. Navarro, “but caring for patients
with liver disease takes the coordinated work
of a team of other physicians, nurses, and care
coordinators throughout the patients’ lives.”
Five coordinators and a social worker support
the Hepatology/Liver Transplant program.
“Before transplant, the Hepatology team works
with gastroenterologists and other referring
doctors to evaluate the patient’s liver disease
through procedures such as endoscopies
and biopsies,” Dr. Navarro explains. In
cases involving liver cancer, physicians

from Interventional Radiology and Medical
Oncology also consult. Using a liver tumor
management system that Jefferson developed,
the team aims to treat the tumor and control
growth so that the patient is strong enough
for transplant. “Dr. Edith Mitchell, the
team’s medical oncologist, has helped provide
innovative chemotherapies, making the program
a beacon for other institutions,” says Dr.
Navarro. “Patients from around the tri-state
area with liver cancers are coming to us for
evaluation for transplant.”
After transplant, the division of GI and
Hepatology provides a great deal of patient
care to manage any complications, look for
signs of infection or rejection, educate the
patient on home care, and follow up at regular
intervals for years to come.
Keeping Jefferson on the leading edge of liver
patient care also requires excellent research
and education. To this end, Jefferson is one of
only 22 institutions in the country to provide a

one-year liver transplant hepatology fellowship
that is approved by the Accreditation Counsel
for Graduate Medical Education.
In research, the division is currently conducting
two NIH-funded studies. The first is exploring
a botanical called silymarin (extracted from milk
thistle) that is thought to benefit non-alcohol
induced steatohepatitis and hepatitis C, both
of which involve inflammation of the liver. This
is a five-year clinical trial, now in its third year.
The other NIH-funded study is in drug-induced
liver injury, meaning liver injury caused by
bad reactions to commonly prescribed drugs.
Patients with drug-induced liver injury are
enrolled and their reaction to a medication,
herbal, or dietary supplement is carefully studied.
With its strengths in liver-patient care,
top-notch hepatology and transplant education,
and nationally funded research, the Jefferson
Hepatology/Liver Transplant program is
positioned to continue its role as a regional
leader in this critical area of care. ■

Celebrating the 25th anniversary of the Delaware Valley’s
first liver transplant, Michael Donahue, the transplant
recipient, remains healthy and active today. Left to right:
Robert Barchi, MD, PhD, TJU President; Cataldo
Doria, MD, PhD, Director, Division of Transplantation;
Mr. Donahue; R. Anthony Carabasi, MD; Tom Lewis,
Hospital President and CEO; Victor Navarro, MD,
Medical Director of Liver Transplantation; and
Charles J. Yeo, MD, Chair of Surgery.

45th Annual Martin E. Rehfuss Lecture
Department Chair Arthur Feldman,
MD, PhD (far left), welcomed Christine
Seidman, MD, Professor of Medicine and
Genetics at Harvard Medical School, as the
45th Annual Martin E. Rehfuss Lecturer on
April 30, 2009. The title of Dr. Seidman’s
lecture was “Hypertrophic Cardiomyopathy
(HCM): A Conversation between Myocytes
and Fibroblasts.” Dr. Seidman researches
the causes of HCM, a disease in which the
heart muscle becomes thickened, a condition

https://jdc.jefferson.edu/translations/vol4/iss2/1
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that can lead to sudden cardiac death. Her
work, done in partnership with her husband
Jonathan Seidman, PhD, helps to improve
diagnosis, provide prognoses, and aid
sudden death risk stratification. The annual
Rehfuss lecture honors the late Dr. Rehfuss,
a Jefferson Medical College faculty member
who gained an international reputation for
his research on the digestive system. Dr.
Rehfuss served as an emeritus professor
until his death in 1964. ■
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A Health Care Industry Veteran Is
Inspired to Support Jefferson Research
Peter Scarperi of Newtown, Pa., has made a
generous pledge to support cardiology research
in the Department’s Center for Translational
Medicine. His interest grows out of decades
of experience working for some of the world’s
most prominent health care corporations.
Mr. Scarperi says that the foundation for his
personal and professional values is what he calls
“the three Js”: the Jesuits (he attended St. Peter’s
College, the Jesuit College of New Jersey) and
the pharmaceutical giant, Johnson & Johnson,
where he spent the first 20 years of his career.
As Chief Financial Officer of McNeil, a
Johnson & Johnson subsidiary, Mr. Scarperi
was part of the team that managed the 1982
Tylenol tampering crisis. A complete product
recall of 31 million bottles was ordered when
the company learned that some capsules had
been injected with cyanide, resulting in seven
deaths. Thanks to decisive action, including the
first tamper-resistant packaging, the company
regained the public’s trust and Tylenol
returned to its market share within one year
as the leading over-the-counter painkiller.
“Our response all came down to the credo
handed down from founder Robert Wood
Johnson,” says Mr. Scarperi, “that our first
and most important responsibility was to our
customers. I learned firsthand the value of
translating such strong values into action.”
Mr. Scarperi also held executive positions at
the international advertising firm Ogilvy &
Mather and Nelson Communications. He

credits his experience at Johnson & Johnson
with guiding him throughout his career, and
notes that these same principles also inform
his decisions today as a philanthropist.
Mr. Scarperi began his relationship with
Jefferson in 2008, when he was looking for a
cardiologist. Through colleagues, he learned
of the excellent reputation of Howard Weitz,
MD, Chief of Cardiology and Director of the
Jefferson Heart Institute. “I was blown away
by how terrific he was,” Mr. Scarperi recalls,
“and I was also inspired by all that the
Department of Medicine was doing.”
When Mr. Scarperi expressed interest in
supporting research, the Department arranged
a meeting with Thomas L. Force, MD, the
James C. Wilson Professor of Medicine and
Clinical Director of the Department’s Center
for Translational Medicine. Mr. Scarperi
invited his daughter, Sheryl Bunca — who
worked for Merck & Co. — to accompany
him, and discovered that Dr. Force and his
daughter were already acquainted. Pleased by
the coincidence, and even more impressed
with the work of the center, Mr. Scarperi
pledged to support Dr. Force’s research.
Mr. Scarperi is particularly interested in
supporting research in areas that have affected
his family, including heart disease, cancer,
and birth defects. “As in the best health
care, I strongly believe that relationships are
extremely important, and I look forward to
a long and close relationship with Jefferson.

Peter Scarperi holds a physician’s cane given to him by
Jefferson in gratitude for his support for cardiology
research. Now a distinguished award, a physician’s
cane historically was hollowed and perforated at the
top. It contained a preparation that allegedly would
protect the physician from contagion.

“I’m happy to play a small part in supporting
advances that we can make today, in order to
benefit the patients of tomorrow.” ■

How to Give
Built on a foundation of compassion and
first-rate care, Jefferson is committed to
discovery, innovation, and learning. One
of only 125 academic medical centers in
the U.S., we strive to go beyond providing
exceptional care as we work to break the
boundaries of our patients’ illnesses.
Learn how you can support this important
work with a gift to Jefferson. Please contact
Margaret Fala, Director of Development for
Medicine, at 215-955-7556 or by e-mail at
Margaret.fala@jefferson.edu.

Published by Jefferson Digital Commons, 2010

Jog to Jeff for John
Lisa Marie DiRusso (left) ran 15 miles to
Jefferson to deliver $1,100 in donations in
memory of her stepfather, who had been a
liver transplant recipient. Calling her run the
“Jog to Jeff for John,” Ms. DiRusso decided
to support research by Victor J. Navarro, MD,
Medical Director of the Hepatology and
Liver Transplantation Program (see article,
page 4). She is shown here with Jefferson
Development Director Margaret Fala. ■

5

Jefferson Translations, Vol. 4 [2010], Iss. 2, Art. 1

Education and Critical Care, Pulmonary, Allergic & Immunologic Diseases

A Physician Leader and Educator Wears Two Hats
The Department of Medicine is fortunate to
benefit from the service of Gregory Kane, MD
in multiple roles. Since 2006 he has directed
the Residency Program and served as Vice
Chair for Education. In 2008 he also assumed
the position of Interim Director of the
Division of Critical Care, Pulmonary, Allergic
& Immunologic Diseases.
“Divisions tend to go through life cycles,”
says Dr. Kane, “and Pulmonary has
undergone significant transitions. I was
honored when Dr. Feldman asked me to
step in during this period and ensure that
Pulmonary continued to live up to our
highest standards, department-wide, for our
core missions of education and patient care.”
He also continues to see patients himself.

A Growing Division and a New
Joint Initiative
Since Dr. Kane took the helm in Pulmonary,
Michael Scharf, MD, Clinical Associate

pulmonary arteries — the arteries that supply
blood to the lungs,” says Dr. Kane. “This
forces the heart to work harder to pump
blood through the lungs, and can lead to right
heart failure.”
The new program serves patients who
need specialized care for both heart and
lung conditions, including access to high
quality echocardiography, and offers joint
consultation by Department Chair and
cardiologist Arthur Feldman, MD, PhD;
Howard Weitz, MD; and David Wiener, MD,
of the Jefferson Heart Institute; and Dr. Awsare.
“We also took part in implementing the
new, department-wide Medical Information
System of electronic records,” Dr. Kane says.
“This significant and exciting development
enables physicians and residents to capture
standard orders, as well as options for specific
medications and consistent care hospital-wide,
while eliminating errors that were more
common with paper communication.”

Under the direction of Gregory Kane, MD, the Residency Program offers individualized career pathway
experiences. Left to right: Amyn Hirani, MD; Rodrigo Cavallazzi, MD; Urvashi Vaid, MD; Dr. Kane;
Sneha Thakkar, MD; Rory Bowers, MD; and Ellina Cheskis, MD.

Professor, and Elisabeth Carr, MD, Assistant
Professor, have joined the staff. They join
Bharat K. Awsare, MD; Sandra Weibel, MD;
Michael Baram, MD; Salvatore Mangione,
MD; and Ritu Grewal, MD.
The Division has recently begun a new
program in pulmonary hypertension in
conjunction with the Jefferson Heart Institute
(JHI). “This serious condition, which involves
both the heart and lungs, constricts the

Residency Program Developments
The Residency program has also seen some
significant changes under Dr. Kane’s
leadership. “We are beginning to implement
new ways of individualizing the residents’
training to fit their unique career interests,”
says Dr. Kane. A set of nine pathways has
been developed, so that after the first year of
residency, which offers core training, residents
can choose from a series of electives that are
customized to their particular career focus.

https://jdc.jefferson.edu/translations/vol4/iss2/1
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“For example,” says Dr. Kane, “a resident
aspiring to an office-based practice can
choose electives that are outpatient-based.
If the resident is interested in basic science,
the program works to identify a laboratory
mentor and a laboratory experience.” Those
interested in clinical research might do an
elective at the Annals of Internal Medicine to
become familiar with the editorial process of a
major medical publication. Residents seeking
a career in clinical research can take part in
the K30 program, led by Pharmacology Chair
Scott Waldman, MD, PhD, which focuses
on the critical skills needed to translate basic
discoveries into clinical treatments, and offers
a Clinical Research Curriculum Award.
“The redesign of education in Internal
Medicine is no longer one-size-fits-all,”
says Dr. Kane. “We wanted to support our
residents by recognizing that they’re going
into careers that are quite varied.”
About 24 residents are on a clinical education
and leadership track, led by Gretchen Deimer,
MD, that offers individualized experiences in
teaching. Ellina Cheskis, MD, finished her
residency after only two years in the research
pathway and then went into the lab to do
research. Resident Sneha Thakkar, MD, spends
half of her time on clinical rotations and the
other half on medical informatics, which uses
technology — such as electronic prescribing
of pharmaceuticals — to improve care, safety,
and efficiency in the hospital. Other pathways
help residents to become a hospitalist or a
public health specialist. The efforts of the
residents will be recorded in a new portfolio
system being developed by Jessica Salt, MD,
to highlight the career accomplishments of
Jefferson’s residents.
This education approach has received national
attention. In November 2008 Dr. Kane and
Donna Williams, MD, presented a workshop
on these career pathways at a national
meeting of program directors as part of
Academic Internal Medicine Week. “The
workshop was well received, ” Dr. Kane says.
“We look forward to continuing to expand
our offerings for each incoming group of
talented residents.” ■
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Length-of-Stay
continued from page 1

The Critical Cooperation of Physicians
From the outset, Dr. Feldman highlighted the
critical role and accountability of the attending
physicians in general, and the Division Directors
specifically. To prepare to implement the
recommendations, he worked with his nine
Division Directors to identify a “physicians’
champion” within the four key in-service teams,
to shepherd the process on a day-to-day basis.

to coordinate this data into a single report.
Ms. Javie notes that former chief residents
David Aziz, Tamara Fisicaro, and Stephanie
Moleski were instrumental in guiding and
implementing this aspect of the initiative.
“This information provides a roadmap for the
hospital to prioritize systems and to identify
policies that need to change to support
appropriate LOS,” says Ms. Javie.

practitioners instead of residents,” explains
Ms. Javie. The next major focus is the creation
of clinical pathways and order sets for our top
three Opportunity Medicare Severity Diagnosis
Related Groups (MS-DRGs). “This patient
classification system identifies resources needed
as part of the prospective payment system
required by Medicare,” she says. The other
insurers have followed Medicare’s lead.

Key Recommendations and Implications
In February of this year, Dr. Feldman convened
a biweekly LOS multidisciplinary working
group to implement the recommendations. Of
the many recommendations and procedural
changes, the following were identified as key:
1. Huddle Rounds
Each of the four multidisciplinary service teams
meets by 8:30 a.m., with the primary goal of
writing discharge orders by 10:00 a.m. for
patients scheduled to go home that day. The
huddle also reviews the team’s other patients
and is proactive regarding newly admitted
patients as well as those scheduled for discharge
the following day. Vice President for Clinical
Resource Management Patrice Miller, BSN,
MSN, MBA, and her chief manager, Mary
O’Brien, have been particularly committed to
making this process work.
“At the conclusion of huddle rounds, all team
members know specifically what they need
to do to facilitate timely patient discharge
and are free to engage in Teaching rounds,
which must also be completed by 10:00 a.m.,”
explains Dr. Feldman.
The changes also improve communications
with each patient. Doctors making rounds
now must routinely tell new patients on their
first day in the hospital what their expected
LOS is. “This helps patients to understand the
‘big picture’ and to organize any family support
needed for transport home from the hospital
as well as follow-up care,” says Ms. Javie.
2. Leveraging Technology
JeffIT’s role has improved the access and
usability of patient charts. Jeffrey Riggio, MD,
worked with Mary McNichol in Information
Systems to include a working LOS in the
patient’s electronic file. This in turn generates
a report with a suggested LOS that the team
uses as a working target.
3. Residents’ Daily Report
The house staff assigned to the teams also
keeps a daily log of any issues that might
contribute to an increased LOS and strives
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The oversight committee for the LOS initiative: (front row, from left) Sharon Millinghausen, RN, MSN,
Vice President, Medicine/Cardiac/Critical Care and Specialty Services; Mary Ann McGinley, PhD, RN, Senior
Vice President and Chief Nursing Officer; Arthur Feldman, MD, PhD, Medicine Chair; Jeffrey Riggio, MD,
Information Systems and Patient Safety; Tamara Fisicaro, MD, former Chief Resident; (back row, from left)
Mary McNichol, Information Systems; Michelle Russo, Rehabilitation Medicine; Robin Becker, RPh, MS,
Pharmacy; Karen Javie, RN, MSN, Vice President for Strategic Initiatives; Michael Rufo, Strategic Initiatives;
Mary O’Brien, Clinical Resource Management; and Reetika Kumar, MD, Internal Medicine.

4. Geographic Placement
“Jefferson’s patient placement protocol needed
updating and an emphasis on management,”
says Ms. Javie. Joe Anton, Director of Patient
Logistics, continues to work closely with bed
placement to assure that patients for various
services are admitted to the appropriate areas.
“This is a more consistent way to manage the
process,” Ms. Javie notes. “It promotes teamwork
while increasing efficiency by minimizing the
need for rounds to travel to multiple units.”

Additional Challenges
In July 2009, the Academic Council on
Graduate Medical Education (ACGME)
reduced the number of patients that residents
and interns are allowed to manage — from 16
to 14. ACGME also decreased the number of
attending physicians that any single resident
would interact with during each day. “To
comply with the ACGME, we had to create
a new Hospitalist-run service, consisting of
our in-hospital specialist physicians and nurse
7

Perspectives to Date
The feedback from every division has been
extremely positive so far. Physicians and other
team members claim that the huddles and new
schedule decrease the number of phone calls
required and make overall communication much
easier. Howard Weitz, MD, Director of the
Division of Cardiology and the Jefferson Heart
Institute, was impressed: “This was the first time
in my 30-plus years at Jefferson that I’ve seen
rounds completed by 10 a.m.,” he says. “This
new, consistent approach is advantageous to all
members of the team.”
“The systemic planning and feedback of
this initiative draw upon the talents of all
players,” Dr. Feldman says. “It not only
maximizes efficiency, but also trains
physicians in best practices and ultimately
empowers us to offer our patients the very
best in coordinated care.” ■
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Faculty News
The Pennsylvania Chapter of the American
College of Physicians has presented Howard
Weitz, MD, Director of the Division of
Cardiology and the Jefferson Heart Institute,
with the Laureate Award for exceptional service
to his patients, community, and profession. A
nationally known clinician and educator, Dr.
Weitz has been at Jefferson for over 30 years.
Wolfgang Bergmeier, PhD,
received the Kenneth M.
Brinkhous Young Investigator
Prize in Thrombosis, which
recognizes outstanding
endeavors by new investigators
in fundamental and applied
research in thrombosis. Dr.
Bergmeier is Assistant Professor of Medicine,
Division of Hematology/Cardeza Foundation
Hemophilia Center.
A study published recently in the journal
Circulation by Walter J. Koch, PhD, Director
of the Center for Translational Medicine, and
his team, led by Giuseppe Rengo, MD, showed
that long-term gene therapy resulted in improved
cardiac function and reversed deterioration of
the heart in rats with heart failure.

New Faculty
The following faculty members have joined the
Department of Medicine as of January 2009:
Cardiology: Danielle Duffy, MD
Endocrinology: Monica Shirodkar, MD
Gastroenterology: Monjur Ahmed, MD
Hematology: Douglass Drelich, MD;
Srikanth Nagalla, MD
Internal Medicine: Gustavo Batista, MD;
Mary Halak, MD; Tamara Stolz Solitro, MD
Nephrology: Stephanie DeLoach, MD
Pulmonary: Elisabeth Carr, MD; Michael
Scharf, MD
Rheumatology: Fabian Mendoza Ballesteros, MD
Center for Translational Medicine:
Kazi Islam, PhD
The new division of Hospital Medicine was
created in July 2009. We welcome Susan
Krekun, MD, Director; Kashif Alauddin, MD;
Loren Chen, MD; Dani Choufani, MD; Arif
Hussain, MD; Austin F. Hwang, MD; Keith
Leung, MD; Anthony Macchiavelli, MD;
Lalkrushna Malaviya, MD; Melanie Wijetunga,
MD; Lim Wong, MD.

Each year, the Jefferson Medical College senior
class commissions a portrait to honor a faculty
member as an outstanding individual, supportive
teacher, and inspirational leader. This year’s
honor went to Joseph A. DeSimone, Jr., MD,
Clinical Assistant Professor of Medicine and
Director of the Infectious Disease Fellowship
Program. The portrait, by artist Joseph Q. Daily,
is on view on the first floor of Alumni Hall.
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